Legislative efforts will continue to push for cannabinoid liberalisation in the Philippines – despite recent comments that approval in principle of the epilepsy drug Epidiolex would be sufficient to cover most matters ...
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
